|
1
|
Rooney DE: Human Cytogenetics: Malignancy
and Acquired Abnormalities. 3rd edition. Oxford University Press;
New York: pp. 372001
|
|
2
|
Sessions J: Chronic myeloid leukemia in
2007. Am J Health Syst Pharm. 64:S4–S9. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lugo T, Pendergast A, Müller A and Witte
O: Tyrosine kinase activity and transformation potency of bcr-abl
oncogene products. Science. 247:1079–1082. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Melo JV, Gordon DE, Cross NC and Goldman
JM: The ABL-BCR fusion gene is expressed in chronic myeloid
leukaemia. Blood. 81:158–165. 1993.PubMed/NCBI
|
|
5
|
Quintas-Cardama A, Kantarjian H, Talpaz M,
O’Brien S, Garcia-Manero G, Verstovsek S, Rios M, Hayes K, Glassman
A, Bekele B, Zhou X and Cortes J: Imatinib mesylate therapy may
overcome the poor prognostic significance of deletions of
derivative chromosome 9 in patients with chronic myelogenous
leukemia. Blood. 105:2281–2286. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Melo J, Hochhaus A, Yun X-H and Goldman J:
Lack of correlation of ABL/BCR expression and response to
interferon-α in chronic myeloid leukaemia. Br J Haematol.
92:684–686. 1996.PubMed/NCBI
|
|
7
|
Sandberg AA: The Chromosomes in Human
Cancer and Leukemia. 2nd edition. Elsevier Science; New York: pp.
151–172. 1990
|
|
8
|
Rege-Cambrim G, Caidano G, Serra A,
Scaravaglio P, Guglielmelli T, Guerrasio A, Giovinazzo B and Saglio
G: Analysis of the p53 in myeloid malignancies associated with
chromosomal abnormalities involving the short arm of chromosome 17.
Leukemia. 8:23–26. 1994.PubMed/NCBI
|
|
9
|
Calabretta B and Perrotti D: The biology
of CML blast crisis. Blood. 103:4010–4022. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Claussen U, Michel S, Mühlig P, Westermann
M, Grummt UW, Kromeyer-Hauschild K and Liehr T: Demystifying
chromosome preparation and the implications for the concept of
chromosome condensation during mitosis. Cytogenet Genome Res.
98:136–146. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shaffer L, Slovak M and Cambell L: ISCN
2009: An International System for Human Cytogenetic Nomenclature.
S. Karger; Basel: 2009
|
|
12
|
Weise A, Mrasek K, Fickelscher I, Claussen
U, Cheung SW, Cai WW, Liehr T and Kosyakova N: Molecular definition
of high-resolution multicolor banding probes: first within the
human DNA sequence anchored FISH banding probe set. J Histochem
Cytochem. 56:487–493. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liehr T, Heller A, Starke H, Rubtsov N,
Trifonov V, Mrasek K, Weise A, Kuechler A and Claussen U:
Microdissection based high resolution multicolor banding for all 24
human chromosomes. Int J Mol Med. 9:335–339. 2002.PubMed/NCBI
|
|
14
|
Mitelman F, Johansson B and Mertens F:
Mitelman Database of Chromosome Aberrations in Cancer. 2009,
http://cgap.nci.nih.gov/chromosomes/Mitelman.
|
|
15
|
Reid AG, Huntly BJ, Grace C, Green AR and
Nacheva EP: Survival implications of molecular heterogeneity in
variant Philadelphia-positive chronic myeloid leukaemia. Br J
Haematol. 121:419–427. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Johansson B, Fioretos T and Mitelman F:
Cytogenetic and molecular genetic evolution of chronic myeloid
leukemia. Acta Haematol. 107:76–94. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Imamura J, Miyoshi I and Koeffler HP: p53
in hematologic malignancies. Blood. 84:24121994.PubMed/NCBI
|
